This site is intended for US healthcare professionals only.
Register

There's more to gout than hyperuricemia

Gout is a chronic disease with a multifactorial pathogenesis1-4

Uric acid, renal function, and inflammation are often interconnected in gout

  • Acute gout flares may increase in frequency and duration and lead to the development of chronic gout1
  • Decreased kidney function is strongly associated with hyperuricemia2
Heyperglycemia and renal insufficiency leading to inflammation
Heyperglycemia and renal insufficiency leading to inflammation
  • In 90% of gout patients, hyperuricemia is related to inadequate renal excretion of uric acid3
  • Neutrophil-mediated inflammation may be a common link between chronic kidney diseases and gout4
Look beyond hyperuricemia in the management of gout

In chronic gout, inflammation can be a debilitating and consistent presence3

Immune-mediated inflammation drives gout pathology and symptoms

  • A key pathologic basis of gout symptoms is neutrophil influx into the joint fluid, which causes a release of inflammatory mediators5
  • Emerging data are showing that chronic inflammation may be present even in asymptomatic gout patients6
Inflammation leading to gout
Inflammation leading to gout

Chronic inflammation can have a devastating impact if left unaddressed

  • Persistent inflammation in gout can lead to chronic synovitis, bony erosion, cartilage damage, and tophi formation3
Inflammation can still persist—even when serum uric acid drops below normal baseline levels7

Get news, updates, and a comprehensive brochure for your patients when you sign up

Register

Important Safety Information for GLOPERBA® (colchicine)

  • Colchicine 0.6 mg oral solution is contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given GLOPERBA.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep GLOPERBA out of the reach of children.
  • Blood dyscrasias, such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia, have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and, if present, consider lowering the dose, temporary interruption, or discontinuation of colchicine.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider lowering the dose, temporary interruption, or discontinuation of GLOPERBA.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

GLOPERBA 0.6 mg oral solution is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied.

GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report suspected adverse reactions, visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information for GLOPERBA.

References: 1. GLOPERBA [package insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; 2019. 2. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. Updated January 2020. Accessed April 7, 2020. 3. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429-2432.

References: 1. Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76(6):801-808. 2. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358-371. 3. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective—a review. J Adv Res. 2017;8(5):495-511. 4. Finn WF. Kidney disease and gout: the role of the innate immune system. Open Urol Nephrol J. 2016;9(suppl 1):12-21. 5. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8(1):S3. 6. Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155-165. 7. Bădulescu M, Macovei L, Rezuş E. Acute gout attack with normal serum uric acid levels. Rev Med Chir Soc Med Nat Iasi. 2014;118(4):942-945.

References: 1. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429-2432. 2. Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155-165. 3. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. 4. GLOPERBA [package insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; 2019.

References: 1. GLOPERBA [package insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; 2019. 2. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. Revised January 17, 2020. Accessed February 7, 2020. 3. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-2432. 4. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2011;125:679-687. 5. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128(5):461-470.

References: 1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. Current through December 2020. Accessed December 7, 2020. 2. GLOPERBA [package insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; 2019.